News
OCS
9.06
-2.27%
-0.21
Stifel Nicolaus Sticks to Their Buy Rating for Oculis Holding (OCS)
TipRanks · 17h ago
Weekly Report: what happened at OCS last week (0921-0925)?
Weekly Report · 18h ago
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
NASDAQ · 5d ago
Weekly Report: what happened at OCS last week (0914-0918)?
Weekly Report · 09/21 10:12
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 09/18 12:31
Oculis Holding Price Target Raised to $39.00/Share From $26.00 by HC Wainwright & Co.
Dow Jones · 09/18 11:02
Oculis Holding Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 09/18 11:02
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39
Benzinga · 09/18 10:53
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aethlon Medical (AEMD), Xenon (XENE) and Oculis Holding (OCS)
TipRanks · 09/18 10:20
Oculis price target raised to $39 from $26 at H.C. Wainwright
TipRanks · 09/18 10:15
Oculis Holding AG: Navigating Through Major Trial Setback
Seeking Alpha · 09/17 20:28
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 09/17 15:05
Weekly Report: what happened at OCS last week (0907-0911)?
Weekly Report · 09/14 10:16
Weekly Report: what happened at OCS last week (0831-0904)?
Weekly Report · 09/07 10:10
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
NASDAQ · 08/31 13:55
Weekly Report: what happened at OCS last week (0824-0828)?
Weekly Report · 08/31 10:17
Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target
TipRanks · 08/24 14:55
Weekly Report: what happened at OCS last week (0817-0821)?
Weekly Report · 08/24 10:18
Oculis Treats First Patient In PIONEER-1 Trial Of Privosegtor In Optic Neuritis; Stock Up
NASDAQ · 08/24 10:15
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Barchart · 08/24 03:00
More
Webull provides a variety of real-time OCS stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.